证券代码：002393 证券简称：力生制药 公告编号：2026-011 天津力生制药股份有限公司 关于磷酸腺嘌呤原料药通过上市申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"本公司"）收到国家药品监督管理局 颁发的关于磷酸腺嘌呤原料药《化学原料药上市申请批准通知书》（通知书编号： 2026YS00104），该品种通过化学原料药上市申请。 二、该品种的基本情况 通用名称：磷酸腺嘌呤 英文名称：Adenine Phosphate 汉语拼音：Linsuan Xianpiaoling 化学名：6-氨基嘌呤磷酸盐 化学结构式： 分子量：233.12 分子式：C5H5N5·H3PO4 CAS 号：70700-30-0 生产企业：天津力生制药股份有限公司 申请内容：化学原料药上市申请 受理号：CYHS2460726 审批结论：通过化学原料药上市申请 1 三、该品种的相关信息 天津力生制药股份有限公司 董事会 2026 年 2 月 7 日 2 磷酸腺嘌呤，曾用名维生素 B4，为核酸和辅酶的组成成分，参与体内 DN ...

数据来源：国家统计局，智研咨询整理 上市公司：渤海化学（600800），桂发祥（002820），力生制药（002393），利安隆（300596），津药 药业（600488），久日新材（688199），赛象科技（002337），长荣股份（300195），建科机械 （300823），津荣天宇（300988），中重科技（603135），恒银科技（603106），广宇发展 （000537），金开新能（600821） 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2016-2025年天津市工业企业数统计图 相关报告：智研咨询发布的《2026-2032年中国工业云行业市场深度评估及投资机会预测报告》 2025年1-12月，天津市工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为6286 个，和上年同 ...

Group 1: Dividend Indices - The Low Volatility Dividend Index (H30269.CSI) includes 50 securities with good liquidity, continuous dividends, moderate payout ratios, positive growth in dividends per share, high dividend yields, and low volatility, with a dividend yield of 4.62% as of February 2 [1] - The Quality Dividend Index (931468.CSI) consists of 50 securities that provide continuous cash dividends, have high payout ratios, and exhibit high profitability, with a dividend yield of 2.93% as of February 3 [1] Group 2: Company Dividend Announcements - RichChip Microelectronics announced a cash dividend of 0.30 CNY per share (tax included), with the record date on February 9, 2026, and the ex-dividend date on February 10, 2026 [1] - Jinhui Wine declared a cash dividend of 0.20 CNY per share (tax included), with the record date on February 9, 2026, and the ex-dividend date on February 10, 2026 [2] - Lifespring Pharmaceutical will distribute a cash dividend of 3.00 CNY for every 10 shares (tax included), with the record date on February 10, 2026, and the ex-dividend date on February 11, 2026 [2] - Guosen Securities announced a cash dividend of 1.00 CNY for every 10 shares (tax included), with the record date on February 10, 2026, and the ex-dividend date on February 11, 2026 [2] - Sentai Co., Ltd. will distribute a cash dividend of 1.30 CNY for every 10 shares (tax included), with the record date on February 10, 2026, and the ex-dividend date on February 11, 2026 [3] - Canqin Technology announced a cash dividend of 0.0375 CNY per share (tax included), with the record date on February 11, 2026, and the ex-dividend date on February 12, 2026 [3]

Group 1 - The A-share market is entering a slow bull cycle driven by a combination of unexpected policy measures and improved market ecology, with a strong start in 2026 reflected in rising indices and increased trading volume [2][11] - The macroeconomic environment is expected to support steady growth, with fiscal policies aimed at boosting investment and consumption, alongside a positive outlook for corporate earnings [2][12] - The policy framework emphasizes a coordinated approach among fiscal, monetary, and capital market policies to sustain market momentum and create structural opportunities, particularly in technology and low-volatility dividend sectors [12][13] Group 2 - In 2025, the overall economic performance showed resilience, with strong service consumption and export growth, despite challenges such as external trade tensions and domestic demand recovery [16][19] - The industrial production sector demonstrated stable growth, with the industrial value-added growth rate remaining positive, indicating a solid supply-side performance that is likely to continue into 2026 [16][19] - The export sector exhibited significant resilience, with a notable increase in exports to emerging markets, while traditional consumer goods showed weaker performance [3][19] Group 3 - Corporate profitability is expected to improve, as evidenced by a return to positive year-on-year growth in industrial profits in December 2025, marking an end to three consecutive years of decline [48][49] - A structural divergence in earnings among A-share companies is emerging, with approximately 40% of companies reporting positive earnings forecasts, indicating a shift in capital towards sectors with clearer performance indicators [51]

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至本公告日，天津力生制药股份有限公司（以下简称"公司"或"本公司"）回购专 用证券账户持股数量为699,980股，根据《中华人民共和国公司法》《深圳证券交易所上市 公司自律监管指引第9号——回购股份》等相关规定，该部分股票不参与本次利润分配。公 司以现有总股本257,586,843股扣除已回购库存股699,980股后的256,886,863股为基数，向 全体股东每10股派3.00元人民币（含税），不送红股，不以公积金转增股本。 2、因公司回购专户的股份不参与2025年前三季度权益分派，本次实际现金分红的总金 额=实际参与分配的总股本*分配比例，即256,886,863股*0.30元/股=77,066,058.90元人民 币；本次权益分派实施后除息价格计算时，每股现金红利应以0.2991847元/股计算（每股现 金红利=现金分红总额/总股本，即77,066,058.90元÷257,586,843股=0.2991847元/股，计算 结果不四舍五入，保留小数点后七位）。在保证本次权益分派方案不变的前提 ...

之 法律意见书 关于 天津力生制药股份有限公司2026年第一次临时股东会 天津市四方君汇律师事务所 Join & High Law Office 关于天津力生制药股份有限公司 2026 年第一次临时股东会之法律意见书 致：天津力生制药股份有限公司 天津四方君汇律师事务所（以下简称"本所"）接受天津力生制药股份有限公司（以下简 称"公司"）委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他规范性文件（以下简称 "法律、法规"）以及《天津力生制药股份有限公司章程》（以下简称"《公司章程》"）有 关规定，就公司召开 2026 年第一次临时股东会（以下简称"本次股东会"）有关事宜出具本 法律意见书。 本法律意见书仅就本次股东会的召集和召开程序、出席本次股东会人员的资格、召集人资 格、会议表决程序是否符合法律、法规及《公司章程》规定，以及表决结果是否合法有效发表 意见，并不对本次股东会所审议的议案内容以及该等议案所表述的相关事实的真实性、准确性 或合法性发表意见。 为出具本法律意见书，本所律师审查了本次股东会相关的文件、资料，并对本次股 ...

天津力生制药股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2026-009 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会未涉及变更以往股东会已通过的决议。 3.本次股东会采取现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间 （1）现场会议：2026年2月2日（星期一）下午3:30开始 （2）网络投票：2026年2月2日（星期一） 其中通过深圳证券交易所交易系统进行网络投票的具体时间为2026年2月2日上午 9:15—9:25,9:30—11:30和13:00—15:00；通过深圳证券交易所互联网投票系统进行网络 投票的具体时间为2026年2月2日9:15～15:00期间的任意时间。 （二）会议出席情况 | 分类 | 人数 | 代表股数（股） | 占公司有表决权股份总数的比例（%） | | --- | --- | --- | --- | | 1.总体出席情况 | 145 | 140,648 ...

天津力生制药股份有限公司 董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于近日收到渤海证券 股份有限公司（以下简称"渤海证券"）出具的《关于变更力生制药IPO项目持续督导保 荐代表人的通知》，具体情况如下： 渤海证券为天津力生制药股份有限公司IPO项目持续督导保荐机构，因募集资金尚 未使用完毕，渤海证券仍就剩余募集资金的使用情况继续履行持续督导责任。 由于原指派的保荐代表人张运发先生正常办理退休，不再担任公司持续督导的保荐 代表人，为保证持续督导工作的有序进行，渤海证券决定指派保荐代表人张化先生接替 其持续督导工作，履行保荐职责。本次变更后，天津力生制药股份有限公司IPO项目持 续督导的保荐代表人为方万磊先生和张化先生。 公司董事会对张运发先生在担任保荐代表人期间所做的工作表示衷心感谢！ 特此公告。 证券代码：002393 证券简称：力生制药 公告编号：2026-008 天津力生制药股份有限公司 关于变更持续督导保荐代表人的公告 2026 年 01 月 31 日 附张化先生简历： 张化先生，保荐 ...

Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

Group 1 - The company, Tianjin Lisheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its drug Aminophylline Tablets (0.1g) to pass the consistency evaluation of quality and efficacy for generic drugs [2] - The drug is classified as a chemical drug and is produced by Tianjin Lisheng Pharmaceutical Co., Ltd. The original drug approval number is Guoyao Zhunzi H12020118 [2] - Aminophylline Tablets are indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and can also be used for asthma caused by cardiogenic pulmonary edema [3] Group 2 - The approval of the drug enhances its market competitiveness for the company [4] - The sales performance of pharmaceutical products may be influenced by changes in the market environment, leading to significant uncertainty [4]